- Home
- JL vs KZIA Comparison
JL vs KZIA Comparison
Compare JL & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JL
- KZIA
- Stock Information
- Founded
- JL 1985
- KZIA 1994
- Country
- JL Hong Kong
- KZIA Australia
- Employees
- JL N/A
- KZIA N/A
- Industry
- JL
- KZIA Biotechnology: Pharmaceutical Preparations
- Sector
- JL
- KZIA Health Care
- Exchange
- JL NYSE
- KZIA Nasdaq
- Market Cap
- JL 10.0M
- KZIA 5.1M
- IPO Year
- JL 2024
- KZIA 1999
- Fundamental
- Price
- JL $6.20
- KZIA $6.75
- Analyst Decision
- JL
- KZIA Strong Buy
- Analyst Count
- JL 0
- KZIA 2
- Target Price
- JL N/A
- KZIA $57.50
- AVG Volume (30 Days)
- JL 16.9K
- KZIA 2.6M
- Earning Date
- JL 07-15-2025
- KZIA 07-15-2025
- Dividend Yield
- JL N/A
- KZIA N/A
- EPS Growth
- JL N/A
- KZIA N/A
- EPS
- JL 0.54
- KZIA N/A
- Revenue
- JL $32,831,195.00
- KZIA $1,549,158.00
- Revenue This Year
- JL N/A
- KZIA N/A
- Revenue Next Year
- JL N/A
- KZIA N/A
- P/E Ratio
- JL $11.47
- KZIA N/A
- Revenue Growth
- JL 7.72
- KZIA 248983.08
- 52 Week Low
- JL $2.33
- KZIA $2.86
- 52 Week High
- JL $13.41
- KZIA $79.00
- Technical
- Relative Strength Index (RSI)
- JL 64.65
- KZIA 51.14
- Support Level
- JL $5.90
- KZIA $5.98
- Resistance Level
- JL $6.38
- KZIA $6.65
- Average True Range (ATR)
- JL 0.37
- KZIA 0.83
- MACD
- JL -0.05
- KZIA -0.29
- Stochastic Oscillator
- JL 71.95
- KZIA 15.40
About JL J-LONG GROUP LIMITED
J-Long Group Ltd is an established distributor in Hong Kong of reflective and non-reflective garment trims including, among others, heat transfers, fabrics, woven labels and tapes, sewing badges, piping, zipper pullers and drawcords. It also offers a wide range of apparel solution services to cater to its customers' needs for reflective and non-reflective garment trims, ranging from market trend analysis, product design and development and production to quality control.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.